Q1 Earnings Forecast for ANIK Issued By Barrington Research

Anika Therapeutics, Inc. (NASDAQ:ANIK) – Investment analysts at Barrington Research issued their Q1 2026 EPS estimates for Anika Therapeutics in a research note issued on Thursday, March 13th. Barrington Research analyst M. Petusky forecasts that the biotechnology company will earn ($0.16) per share for the quarter. Barrington Research has a “Outperform” rating and a $20.00 price target on the stock. The consensus estimate for Anika Therapeutics’ current full-year earnings is ($0.84) per share. Barrington Research also issued estimates for Anika Therapeutics’ Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2027 earnings at ($0.45) EPS.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings data on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.13). Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%. The firm had revenue of $30.60 million for the quarter, compared to analyst estimates of $29.00 million.

Separately, StockNews.com upgraded shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday.

Anika Therapeutics Stock Performance

Shares of ANIK stock opened at $15.91 on Monday. The firm’s 50 day moving average price is $16.90 and its two-hundred day moving average price is $19.47. The stock has a market cap of $233.02 million, a PE ratio of -2.39 and a beta of 0.95. Anika Therapeutics has a 52-week low of $14.95 and a 52-week high of $29.11.

Institutional Investors Weigh In On Anika Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. R Squared Ltd acquired a new stake in shares of Anika Therapeutics during the fourth quarter worth $27,000. Aquatic Capital Management LLC bought a new position in shares of Anika Therapeutics in the 4th quarter valued at about $42,000. Tower Research Capital LLC TRC grew its position in shares of Anika Therapeutics by 412.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,890 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 2,326 shares during the period. Quest Partners LLC grew its position in shares of Anika Therapeutics by 115.8% in the 3rd quarter. Quest Partners LLC now owns 6,904 shares of the biotechnology company’s stock valued at $171,000 after acquiring an additional 3,705 shares during the period. Finally, Wells Fargo & Company MN grew its position in shares of Anika Therapeutics by 31.1% in the 4th quarter. Wells Fargo & Company MN now owns 7,421 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 1,759 shares during the period. 91.53% of the stock is currently owned by institutional investors and hedge funds.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.